4C Medical's AltaValve First In Human Experience to be Presented at TCT 2018

BROOKLYN PARK, Minn., Sept. 13, 2018 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its AltaValve™, a transcatheter mitral valve replacement (TMVR) technology, will be highlighted in the following presentations at the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 21-25, 2018 in San Diego, CA:

• Friday, September 21, 2018, @ 3:45pm during Innovation Sessions:
• "4C Medical's AltaValve: The First Human Experience" by Dr. Josep Rodés-Cabau
• Sunday, September 23, 2018 @ 3:50pm during Edited Taped Cases:
• "AltaValve TMVR" presented by Dr. Josep Rodés-Cabau
• Monday, September 24, 2018 @ 10:12am during Didactic Session: Transcatheter Mitral Valve Therapies, Part 2 - TMVR:
• "AltaValve: Device Attributes, Implant Procedure, and First-in-Human" presented by Dr. Philippe Généreux

Josep Rodés-Cabau, MD, is the Director of Catheterization and Interventional Laboratories in Quebec Heart and Lung Institute, Associate Professor of Medicine of Laval University and Canadian Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions (Quebec City, Quebec, Canada).

Philippe Généreux, MD, is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).

In contrast with other TMVR devices, the AltaValve is the first mitral regurgitation (MR) treatment device that is placed in the left atrium, thus preserving the left ventricle. Furthermore, due to supra-annular positioning of the valve, AltaValve avoids issues related to the complexity and dynamics of the mitral annulus, making it suitable for patients independent of their MR mechanism. The AltaValve is a self-expanding device that may be inserted into the left atrium using either a transseptal or a transapical delivery system.

About 4C Medical Technologies, Inc.

4C Medical is a medical device company developing minimally invasive therapies for structural heart disease. Focusing initially on MR therapy and subsequently on tricuspid regurgitation therapy. The company's implant is the first MR therapy with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle, eliminating known issues associated with TMVR technologies which rely on placement and fixation in the native mitral annulus and left ventricle.  

SOURCE 4C Medical Technologies, Inc.

Related Links

http://www.4cmed.com